1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cardax Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Cardax Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 22 pages

Cardax Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Cardax Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Cardax Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cardax Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cardax Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cardax Pharmaceuticals, Inc. - Brief Cardax Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cardax Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cardax Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cardax Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Cardax Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cardax Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cardax Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cardax Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cardax Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Cardax Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Cardax Pharmaceuticals, Inc. Snapshot 4
Cardax Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Cardax Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Cardax Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Cardax Pharmaceuticals, Inc. - Pipeline Products Glance 9
Cardax Pharmaceuticals, Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Cardax Pharmaceuticals, Inc. - Drug Profiles 10
CDX-085 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
CDX-303 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
CDX-505 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Cardax Pharmaceuticals, Inc. - Pipeline Analysis 13
Cardax Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 13
Cardax Pharmaceuticals, Inc. - Pipeline Products By Target 15
Cardax Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 16
Cardax Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 17
Cardax Pharmaceuticals, Inc. - Recent Pipeline Updates 18
Cardax Pharmaceuticals, Inc. - Dormant Projects 19
Cardax Pharmaceuticals, Inc. - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22



List of Tables

Cardax Pharmaceuticals, Inc., Key Information 4
Cardax Pharmaceuticals, Inc., Key Facts 4
Cardax Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Cardax Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Cardax Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Cardax Pharmaceuticals, Inc. - Preclinical, 2013 9
Cardax Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 14
Cardax Pharmaceuticals, Inc. - Pipeline By Target, 2013 15
Cardax Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 16
Cardax Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 17
Cardax Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 18
Cardax Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 19



List of Figures

Cardax Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Cardax Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Cardax Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Cardax Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 13

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.